bluuebunny/crossref_metadata_2025_split huggingface dataset:
Breast Density, Ki67 and Larger Extensions of Breast Cancer.
Authors: Mameri C. , Mameri C. , Mameri C. , Sobral L. , Chambo D. , Totola H. , Mameri Filho J. 
Published: December 2010

Abstract
Background: Studying breast cancer, our data has demonstrated higher occurrence of large extensions and/or multiple synchronic malignant lesions in dense breasts. Following this investigation, we decided to correlate breast density with Ki67 on tumor specimens and disease extent on MRI. Methods: From August 2005 to April 2009, 193 consecutive patients diagnosed with breast cancer were evaluated about number and size of breast malignant lesions, about fibroglandular (FG) density on Mammography and about proliferation marker on immunohistochemistry of tumor cells. Fibroglandular density was classified using criteria: &lt;50%; &gt;50%. All patients had evaluation of hormonal receptors (estrogen and progesterone), HER2/neu and Ki67 on immunohistochemistry of tumor blocks. They were also submitted to bilateral breast MRI in 1.5 T Excite/GE equipment, 5 sequences FSPGR (90 seconds each, 1 preinjection, 4 postinjection of gadolinium 0.16 mM/kg, 3.5/0 thickness) to evaluate size of primary lesion and presence of additional malignant foci. Additional findings were submitted to pathological examination (core or excisional biopsy). Results: Among 193 patients, 66 (34%) presented FG density &lt;50% and 127 (66%) had FG density &gt;50%. Eighty one patients (42%) presented large single tumor (35 cases) and/or multiple synchronic malignant lesions (46 cases), which 16/81 (19%) had FG density &lt;50% and 65/81 (81%) had FB density &gt;50%. In 112/193 patients (58%) with small single tumor on MRI, 66 (59%) had density &gt;50%. Expression of Ki67 was 30% positive or higher in 17/66 patients (25,7%) with FG density &lt;50% and in 70/127 patients (55%) with FB density &gt;50%. Correlation between high expression of Ki67 (30% or higher) and extent was significant for patients with large single tumor (17/35=48,5%), but not for patients with multiple synchronic lesions (11/46=24%). Expression of Ki67 was 30% positive or higher associated with HER2 overexpression (3+) or with triple negative tumors in 95% of both conditions (multiple synchronic or larger single tumors). Conclusions: This study demonstrated that dense breasts are associated with larger extensions of breast cancer and suggests that FB density can be correlated to higher expressions of Ki67 on immunohistochemistry, especially in single tumors.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6043.
Consistency of Effect of Docetaxel-Containing Adjuvant Chemotherapy in Patients with Early Stage Breast Cancer Independent of Nodal Status: Meta-Analysis of 12 Randomized Clinical Trials.
Authors: Laporte S. , Jones S. , Chapelle C. , Jacquin J. , Martín M. 
Published: December 2010

Abstract
BackgroundUp to now taxanes have been extensively evaluated in the treatment of node-positive early-stage breast cancers (ESBC). Recently, more data have become available in patients with node-negative as well as node-positive ESBC treated with docetaxel-based regimens. We conducted a meta-analysis of randomized ESBC trials in order to evaluate the efficacy of adjuvant docetaxel-based regimens in terms of disease-free survival (DFS), overall survival (OS), and whether treatment effects are maintained across different nodal status subpopulations.MethodsStudies including at least 100 patients and presented or published before December 31, 2008 were retrieved by searching the MEDLINE, CANCERLIT, and Cochrane Library databases and the proceedings of major conferences. Outcomes recorded were DFS and OS. We extracted hazard ratios (HR) and 95% CIs for DFS and OS from each trial and obtained pooled estimates using an inverse-variance model in a random effect model. In trials including both node-positive and node-negative breast cancers, and with nodal status as a clear stratification factor at randomization, HR were extracted for each subpopulation separately. A HR less than 1 indicated that docetaxel was superior to the no-taxane regimen.ResultsTwelve randomized phase III studies were included in the meta-analysis (20 698 patients). Three subsets of trials/strata were used: node-positive (10 trials or strata, 14 787 patients), node-negative (4 trials/strata, 4 274 patients), or combination of both (2 trials, 1 637 patients). Overall, the pooled HR estimate [95% CI] for DFS was 0.81 [0.74;0.89] (P&lt;0.001) in favor of docetaxel-based chemotherapy. The results are the same for node-positive (HR=0.84 [0.77;0.91]) and node-negative breast cancer (HR=0.84 [0.72;0.99]). The overall estimated HR for OS was 0.81 [0.72;0.91] (P&lt;0.001). Results by nodal status subpopulations are awaited.ConclusionThis meta-analysis of 12 recent randomized phase III trials shows that adjuvant docetaxel-based chemotherapy compared to regimens without taxanes is associated with an improvement in DFS and OS independent of nodal status. Other analyses will also be presented.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 605.
New HER2 Assay Using Trastuzumab for the Selection of Trastuzumab Responding Breast Cancer: The Positivity Is Significantly Associated with Pathologic Complete Response after Preoperative Chemotherapy.
Authors: Kim S. , Baek N. , Kwon B. , Kwon Y. , Ro J. , Park I. , Lee E. 
Published: December 2010

Abstract
Background:The evaluation of HER2 status is required for trastuzumab therapy in breast cancer. Although there are a few methods for an evaluation of HER2 status, theoretically the better method would be to check trastuzumab uptake itself in the tumor after trastuzumab administration. Therefore, we developed a different HER2 test (QHerceptest) using trastuzumab to improve an accuracy in the selection of patient for trastuzumab therapy.Patients and Methods:31 patients with HER2 positive (IHC 3+: 19 and IHC 2+ with FISH positive: 12) early breast cancer who were enrolled in a phase II preoperative paclitaxel, gemcitabin and trastuzumab (PGH) combination chemotherapy trial were evaluated. The pre-chemotherapy tumor specimens were obtained from the breast mass (n=24) or metastatic lymph nodes (n=7). After completing 6 cycles of PGH therapy, all patients underwent breast conserving surgery or mastectomy. We applied trastuzumab and Quantum dot conjugated goat anti-human IgG (QD-IgG, 655nm, Invitrogen) in the process of immunuhistochemistry for HER2 using formalin-fixed paraffin embedded specimen. After antigen retrieval, trastuzuamb was applied followed by QD-IgG. The result of QHerceptest was scored as negative, weak positive, moderate positive, or strong positive, and its relative uptake (RU) were quantified by imaging analysis program (Q-IHC, http://www.bio-miblab.org).Results:The uptake of trastuzumab by QHerceptest was heterogenous, varying between 1.3% to 193.7%. Twenty one of 31 (67.7%) patients achieved pathologic complete response (pCR): 11 of 12 patients (91.7%) with QHerceptest strong positive tumors, 6 of 9 patients (66.7%) with QHerceptest moderate positive tumors, and 4 of 7 patients (57.1%) with QHerceptest weak positive tumors, and none of 3 patients (9.4%) with QHerceptest negative tumors (p=0.0203). Besides, RU was significantly different between non-pCR and pCR groups (43.9±38.3, 80.8±47.1, p=0.0396)Conclusion:We developed a new HER2 assay using trastuzumab and applied to clinical specimen. This assay showed heterogenous trastuzumab uptake in this patient population. Although the data need to be verified by further study, the assay could possibly eliminate patients among HER2 positive breast cancer who will not get benefit by trastuzumab .This study was supported by NCC Grant No 0710292-2 and NCC Grant No 0610240.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6050.
HER2+ Tumors with Lack Steroid Receptors Showed a Shorter DFS but Similar OS Compared to HER2+ Tumors That Also Express ER and/or PR.
Authors: Gómez H. , Vigil C. , Cruz W. , Velarde R. , Abugattas J. , Suazo J. , Vidaurre T. , Neciosup S. , Vallejos C. 
Published: December 2010

Abstract
Background: HER2 expression is widely measured on tumor tissue from breast cancer patients since it gives prognostic and predictive information. Data suggest that breast cancer growth is regulated by the coordinated action of the estrogen receptor (ER) and receptor tyrosine kinase signaling pathways. The aim of this retrospective analysis was to evaluate the additional prognostic value of the ER/PR status for the subset of patients with HER2-positive tumors.Methods: From 2000-2002, 203 breast tumors were tested for HER2 and steroid receptors levels. HER2-positivity was defined as ≥2 copies of the HER2 gene by FISH or 3+ by IHC. A cut-off point of 10 % was used as positivity for ER and/or progesterone receptor (PR) levels.Results: Among the 203 patients, 103 had HER2+/ER-/PR- tumors and 100 had HER2+/ER+ and/or PR+ tumors. Patients' characteristics were comparable between the two groups as far as age, menopausal status, pTNM (stage I-II-III) status and type of initial therapy. All patients had surgery followed by standard chemotherapy and radiotherapy and hormonal therapy if the tumor was ER+ or PR+. No patients received adjuvant treatment with trastuzumab. The median follow-up for the entire cohort was 73 months (range 12-110). Comparisons of disease-free survival (DFS), overall survival (OS) as well as site of first recurrence were made between the two groups. The 5-year DFS was statistically different between the two groups: 69.9% for HER2+/ER-/PR- patients and 81.0% for the HER2+/ER+ and/or PR+ (p=0.037). The 5-year OS was not different between the two groups with 82.5% for HER2+/ER-/PR- patients and 86.0% for the HER2/ER+ and/or PR+ (p=0.402).Conclusions: Patients with HER2+/ER-/PR- breast cancers treated with surgery and standard adjuvant chemotherapy exhibit a statistically worse DFS compared to patients with HER2+/ER+ and/or PR+ tumors. However, overall survival was similar in both groups; additional factors should be evaluated to explain this finding.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6052.
VARS2 V552V Variant as a Prognostic Marker in Patients with Early Breast Cancer.
Authors: Chae Y. , Park H. , Jeong J. , Yang J. , Lee M. , Park J. , Kim S. 
Published: December 2010

Abstract
Purpose: The present study analyzed the polymorphisms of DNA repair genes and their impact on survival of patients with early breast cancer.Patients and methods: A total of 240 patients with surgically resected early invasive ductal breast cancer were enrolled in the present study, where patients who underwent neoadjuvant treatment were excluded. The genomic DNA was extracted from paraffin-embedded tumor-free tissue or blood, and thirteen single nucleotide polymorphisms of 12 DNA repair genes were determined using the Sequenom Mass array system.Results: Among the target SNPs, VARS2 rs2074511 and POLE rs5744857 were found to correlate with relapse-free survival (RFS) after curative surgery in the log-rank test. There was no difference in the clinical and tumor characteristics according to the genotypes of these two coding variants except for the higher incidence of positive ER in patients with the GG genotype of POLE rs5744857 (p = 0.025). Multivariate analysis showed that the GG genotype of VARS2 V552V (rs2301717) was marginally associated with a better RFS than the combined AA and AG genotype (HR = 0.298; 95% CI = 0.089-0.995; p = 0.049). However, there was no significant association with overall survival.Conclusion: VARS2 V552V may be considered as a prognostic factor of survival in patients with early breast cancer.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6055.
Single Nucleotide Polymorphism (SNP) in RASSF1 and Clinical Outcomes of Breast Cancer Patients Treated with Neoadjuvant Docetaxel/Doxorubicin Chemotherapy.
Authors: Keam B. , Kim H. , Im S. , Im S. , Han S. , Han S. , Oh D. , Oh D. , Kim J. , Kim J. , Lee S. , Lee S. , Chie E. , Chie E. , Han W. , Han W. , Kim D. , Kim D. , Cho N. , Moon W. , Kim T. , Kim T. , Park I. , Noh D. , Noh D. , Heo D. , Heo D. , Ha S. , Ha S. , Bang Y. , Bang Y. 
Published: December 2010

Abstract
PurposeThe tumor suppressor gene RASSF1 (Ras association domain family member 1) regulates cell cycle, progression, apoptosis, and microtubule stability, and is inactivated by promoter hypermethylation in breast cancer. We analyzed the SNPs in RASSF1 and their predictive and prognostic value in stage II or III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapyMethodsA total of 139 stage II or III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. The patients received three cycles of neoadjuvant chemotherapy followed by curative surgery, and received additional three cycles of docetaxel/doxorubicin chemotherapy as an adjuvant. Germline DNA from peripheral blood mononuclear cells was extracted. The genotypes were performed using Illumina GoldenGate® Assay. We analyzed 3 SNPs in RASSF1 genes: rs3213621 T&gt;C in 3'UTR, rs2073499 G&gt;A in intron, and rs2073498 C&gt;A in exon 3 Ala133Ser.ResultsThe overall radiologic response rate (RR) for neoadjuvant chemotherapy was 79.8% and 10 patients (7.2%) achieved a pathologic complete remission (pCR). None of the SNPs were correlated with radiologic RR or pCR rate. SNP in intron of RASSF1 (rs2073499) was associated with relapse free survival (RFS). RFS was longer in GA/AA genotype than GG genotype (Hazard ratio [HR]=0.374, p=0.034) After adjusting age and hormone status, prognostic value of RASSF1 SNP remained significant (HR=0.393, p=0.050). Other two SNPs were not significantly associated with RFS.ConclusionsThe GA/AA genotype in SNP of RASSF1 (rs2073499) is associated with significantly longer RFS than the GG genotype. Further research is warranted to identify the biologic characteristics of RASSF1.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6061.
The Developing Nature of Menstrual and Reproductive Factors Associated with Breast Cancer Risk among Women in an Urban Region of China.
Authors: Gao J. , Zhang B. , Lian R. , Yue R. , Liang X. , Wang G. 
Published: December 2010

Abstract
Introduction: The incidence rate of female breast cancer has increased rapidly over the past 20 years in China. It has become the leading cause of newly diagnosed cancer and a major cause of mortality among women in some large Chinese cities with higher socio-economic status. This was partly explained by the change of lifestyle and reproductive risk factors. However, little data exists on the extent to which the menstrual and reproductive factors with breast cancer risk have changed in other less developed Chinese cities.Method: One cross sectional study was conducted in urban region of Taiyuan of China from September 2008 to March 2009. One thousand and five hundreds healthy women were invited to complete a self-administered questionnaire. Participants' characteristics, including age, education, occupation, weight, height, age at menarche, age at first birth, parity, duration of breastfeeding, and age at menopause were collected and analyzed. Study subjects were divided into six groups: younger than or equal to 20, 21 to 30, 31 to 40, 41 to 50, 51 to 60 and older than 60 years old.Results: One thousand four hundreds and twenty eight women returned the questionnaire. The response rate was 95.2%. Median age of women in this study was 39 years old (range: 16 – 86 years old). There was a 4.8cm difference in the mean height between women born in 1990s and 1940s. The average age at menarche dropped from 16 years for women aged above 60 to 14.3 years for those younger than 20 years old. The average birth rate markedly decreased from 4.4 births per woman in the 1960s to 1.1 births per woman in the 1990s. The mean age at first birth increased 5.6 years through the period from the 1940s to 1980s. The breastfeeding time significantly reduced from 20.3 months to 3.6 months over 40 years.Conclusion: This study indicates that there has been significant change in the menstrual and reproductive factors associated with breast cancer risk in the last 40 years. These changes will certainly influence the incidence rate of breast cancer in the local city. Therefore, measures are needed to enhance the awareness of breast cancer and its early-detection methods among the urban region women in China.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6068.
Prospective Study of Vitamin D Levels in Sydney Patients with a New Diagnosis of Breast Cancer.
Authors: Harris C. , Lynch J. , Thomas D. 
Published: December 2010

Abstract
Background: Vitamin D deficiency has been associated with malignancy in many reported studies. More recently an association has emerged between low levels of vitamin D and poorer outcome in breast cancer. Australian recommendations for vitamin D are defined as deficient if 25-OH vitamin D levels are ≤ 50nmol/L and severely deficient if ≤12.5nmol/L. We hypothesise that lower levels of vitamin D are associated with a more advanced disease at diagnosis.Methods: We conducted a prospective study in patients with a new diagnosis of breast cancer who presented to our area health service from January 1st 2008 to October 1st 2008. Patients were also included if their diagnosis occurred in the preceding 6 months and were referred onto the multidisciplinary breast care team for treatment in this time period. 25-OH vitamin D levels were measured for each patient during staging and details collected about each patients breast cancer characteristics. Patients completed a questionnaire assessing comorbidities, medications, diet and lifestyle effects which were likely to influence vitamin D levels. We used stage, disease requiring chemotherapy, and the need for mastectomy as surrogate endpoints for assessing disease extent.Results: 166 patients were recruited with a median age of 58 (range 21-100). The median vitamin D level was 48 (range of &lt;10 to 170). 53% (n=88) patient were deficient (25-OH vitamin D ≤ 50nmol/L), 2% (n=3) patients were severely deficient (25-OH vitamin D ≤ 12.5nmol/L) and only 14% had sufficient levels (25-OH vitamin D &gt;75nmol/L). The majority of patients reported the recommended sun exposure during weekdays (77%) and on weekends (86%). Most were had fair or medium skin tones (83%) and less than 10% wore sunscreen daily. Only 22% of patients had a potential identifiable cause for vitamin D deficiency. Vitamin D levels did not correlate directly with stage of disease (RR 1.03, 95% CI 0.86-1.23 p=0.85), however other surrogates for more advanced disease including the need for more aggressive treatment either with chemotherapy (RR 1.30, 95% CI 1.05-1.61 p=0.02) or mastectomy (RR 1.67 95% CI 1.03-2.7 p=0.04) were associated with low levels of vitamin D.Conclusions: Vitamin D deficiency is very prevalent in our population of patients diagnosed with breast cancer, despite perceived adequate sun exposure and lack of obvious cause. Lower levels of vitamin D did not directly correlate with more advanced stage of the disease at diagnosis; however patients with low levels of vitamin D were more likely to need chemotherapy or require mastectomy, which may suggest a more aggressive disease. The cause of breast cancer remains multifactorial and vitamin D deficiency is only one part of this complex disease.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6071.
An Intervention for Moving Long Overdue Women To Get a Mammogram.
Authors: Costanza M. , Luckmann R. , White M. , Rosal M. , LaPelle N. , Cranos C. 
Published: December 2010

Abstract
Background: While there is substantial evidence that mammography screening decreases breast cancer mortality, as many 15 million American women are overdue for a biennial mammogram. This pilot study addressed the usefulness of a computer-assisted telephone counseling program in motivating reluctant or resistant women to get a mammogram.Methods: 127 women, aged 45-79, enrolled in primary care practices and without a documented mammogram for &gt;=27 months were identified, approved by providers and eligible for study. All women had adequate health insurance and all had received a screening recommendation from their provider. The intervention included a mailed educational booklet followed by tailored counseling call, motivational interviewing and facilitated short-interval test scheduling. Using a computer-assisted telephone counseling program, the counselor identified the subject's stage of readiness to get a mammogram, reviewed the booklet in detail, clarified any misinformation and discussed specific barriers. At the conclusion of counseling, the counselor used motivational interviewing techniques to reconcile subjects' stated values with their stage of readiness. Outcome measures included stage change and completed mammograms within 12 months of the call as documented in the claims data.Results: Of the 127 eligible women, 45 (35%) agreed to counseling. 11% of these women had never had a mammogram, 7% had not had one in 48-59 months; 62% had not had one in&gt;=60 months. At the start of the call, 11% had decided not to get mammograms, 16% were undecided about whether to get one, 44% were planning to get one but had no specific appointment and 4% had a mammogram appointment. Of these 45 women, 73% moved 1 or more stages closer to getting a mammogram. Of 13 women initially not planning to get a mammogram, 3 scheduled a mammogram and 3 stated an intention to get one. 75 % of women who scheduled a mammogram with the counselor went on to complete the test. 58% of the 45 counseled women actually got a mammogram. Of the 82 eligible women who refused to be in the study or did not respond to the telephone calls, only 21% got a mammogram. (57.8% vs. 21.3%, p&lt;.001)Conclusions: It is possible to reach mammogram-reluctant women and to move them to complete a mammogram. Many of the counseled women were not against having mammograms but had no definite plans to get one. Women who schedule a mammogram are likely to keep the appointment. Given the low rate of mammography in those refusing to participate or not answering our calls, we suspect this group held a large number of mammogram-resistant women.For these women, additional interventions, such a monetary enhancement might prove useful. A prospective controlled trial to evaluate this intervention is currently underway. Supportedby NIH R21-100286
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6076.